JW Therapeutics announced the completion of a US$100 million Series B round of financing, the investment was co-led by CPE and Mirae Asset, jointed by CR-CP Life Science Fund and Oriza Holdings, as well as existing investors including Loyal Valley Capital, Temasek, Sequoia Capital China, ARCH Venture Partners, Juno Therapeutics, a Bristol Myers Squibb company, and WuXi AppTec.
JW Therapeutics will use the proceeds to further advance the clinical trials of its lead product JWCAR029 (a CAR-T cell product targeting CD19), further build-out a pipeline, and gear up to establish commercialization capabilities to support product launch.
James Li, Co-Founder and CEO of JW Therapeutics, commented: “We are very pleased to welcome our new investors and, by working together, we hope to accelerate our product development and serve Chinese patients.”